Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA®▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU)
- EMEA Innovative Medicine
- Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA®▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU)
Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA®▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU)
- X (Twitter)
Copy link